Industry
Alembic Pharma Q2 net surges 81% to ₹335 crore
ED action in Reliance Anil Ambani Group cases | Explained
CERT-In calls for testing AI agents for unauthorised tool use, privilege abuse
India secures $400-bn investment commitments in renewables; ALMM review in 15 days
Apollo Hospitals’ Q2 revenue rises 23%; profit up 32% on broad-based growth
Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue
The Hindu - Industry·5 Nov 2026
The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
More news in Industry
Alembic Pharma Q2 net surges 81% to ₹335 croreED action in Reliance Anil Ambani Group cases | ExplainedCERT-In calls for testing AI agents for unauthorised tool use, privilege abuseIndia secures $400-bn investment commitments in renewables; ALMM review in 15 daysApollo Hospitals’ Q2 revenue rises 23%; profit up 32% on broad-based growth